Citius Oncology, Inc. (CTOR)

Market Cap	110.52M
Revenue (ttm)	n/a
Net Income (ttm)	-19.52M
Shares Out	71.30M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,108
Open	1.560
Previous Close	1.650
Day's Range	1.550 - 1.655
52-Week Range	1.530 - 49.000
Beta	n/a
Analysts	Strong Buy
Price Target	6.00 (+287.1%)
Earnings Date	Aug 12, 2024

About CTOR

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.

• Founded: 2021
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: CTOR

Financial Performance

Financial numbers in USD

Analyst Forecast

According to one analyst, the rating for CTOR stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(287.10% upside)

Analyst Consensus: Strong Buy